VIEKIRA with or without ribavirin indicated for the treatment of patients with genotype 1 chronic hepatitis C infection including those with compensated cirrhosis.
Includes ombitsavir, a hepatitis C virus NS5A inhibitior, paritaprevir, a hepatitis C virus NS3/4 protease inhibitor, ritonavir, a CYP3A inhibitior and dasabuvir, a hepatitis C virus non-nucleoside NS5B Palm polymerase inhibitior.
Not recommended for usa in patients with decompensated liver disease.
Recommended dose: two ombitsavir, paritaprevir, ritonavir 12.5/75/50 mg tablets once daily in the morning and one dasabuvir 250 mg tablet twice daily with a meal without regard to fat or calorie content.